Joyce Philip, MD
Hematology & Oncology · Appleton, WINPI 1235524406
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Pfizer accounts for 60.1% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $5,272, more than ten times the $191 reported in 2022.
Across 33 payments — averaging $207.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Genmab U.S., Inc.$658
- Johnson & Johnson$398
- AbbVie$381
- Sanofi$191
- Karyopharm Therapeutics Inc.$126
- plus $977 from 12 others
Across 35 payments — averaging $3747.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$78K
- GSK$54K
What the payments were for
- Consulting fees$3,92557%
- Food & beverage$2,84642%
- Education$791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $4,120 |
| Genmab U.S., Inc. | 6 | $658 |
| Johnson & Johnson | 4 | $398 |
| AbbVie | 4 | $381 |
| Sanofi | 2 | $191 |
| Karyopharm Therapeutics Inc. | 1 | $126 |
| Eisai Inc. | 1 | $125 |
| Incyte Corporation | 1 | $110 |
| ADC Therapeutics America, Inc. | 1 | $103 |
| Geron Corporation | 1 | $103 |
| E.r. Squibb & Sons, L.L.C. | 1 | $90 |
| Tempus AI, Inc | 1 | $89 |
| Sumitomo Pharma America, Inc. | 1 | $89 |
| Novocure Inc. | 1 | $81 |
| Bayer | 1 | $78 |
| AstraZeneca | 1 | $71 |
| Boston Scientific | 1 | $19 |
| Gilead | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,850 in reported general payments places this provider in the 75th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 12 | $180,913 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 32 | $64,285 |
| VenclextaVenetoclax | 12 | $54,723 |
| EliquisApixaban | 18 | $17,777 |
| XareltoRivaroxaban | 13 | $8,295 |
| Ondansetron Hcl | 62 | $1,460 |
| Prochlorperazine Maleate | 63 | $1,255 |
| Hydroxyurea | 38 | $1,250 |
| Dexamethasone | 94 | $1,028 |
| Acyclovir | 34 | $291 |
| Oxycodone Hcl | 11 | $79 |
| Furosemide | 25 | $71 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $64 |
| Allopurinol | 14 | $55 |
| Prednisone | 14 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $381 | $54,72312 claims |
| PfizerEliquis | $4,120 | $17,77718 claims |
| Johnson & JohnsonXarelto | $398 | $8,29513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Appleton
- Yazhini VallatharasuAppleton$5K
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.